Effect of beta-blocker therapy in patients with coronary artery disease in New York heart association classes II and III

American Journal of Cardiology

Volumn 81, Issue 12, 1998, Pages 1455-1460

  Haim, Moti ^a   Shotan, Avraham ^a   Boyko, Valentina ^a   Reicher Reiss, Henrietta ^a   Benderly, Michal ^a   Goldbourt, Uri ^a   Behar, Solomon ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT;

ADRENERGIC BETA-ANTAGONISTS; AGED; COHORT STUDIES; CORONARY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; RISK; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032525840     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00205-7     Document Type: Article

References (30)

1. 1. Epstein SE, Braunwald E. The effect of beta-adrenergic blockade on patterns of urinary sodium excretion. Ann Intern Med 1966;65:20-27.
2. 2. Cohn JN, Levine B, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-823.
3. 3. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmerson A, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-1456.
4. 4. Wissenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, Rothlisberger C, Skudicky D, Sareli P. Long-term (3 month) effects of new beta-blocker (Nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993;21:1094-1100.
5. 5. Doughty RN, MacMahon S, Sharpe N. Beta-Blockers in heart failure: promising or proved? J Am Coll Cardiol 1994;23:814-821.
6. 6. Waagstein F, Caidahl K, Wallentin I, Bergh C-H, Hjalmerson A. Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989; 80:551-563.
7. 7. Persson H, Rythe'n-Alder E, Melcher A, Erhardt L. Effects of β receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol. Br Heart J 1995;74:140-148.
8. 8. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-218.
9. 9. The Xamoterol in severe heart failure study group. Xamoterol in severe heart failure. Lancet 1990;336:1-6.
10. 10. CIBIS investigators and committees. A randomized trial of β-blockade in heart failure. The cardiac insufficiency bisoprostol study (CIBIS). Circulation 1994;90:1765-1773.
11. 11. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503-510.
12. 12. Packer M, Bristow MR, Cohn JN, Golucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the carvedilol heart failure study group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355.
13. 13. Colucci WS, Packer M, Bristow MR, Gilbert M, Cohn JN, Fowler MB, Krucger SK, Hershberger R, Urettsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA, for the US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-2806.
14. 14. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH, for the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation 1996;94:2793-2799.
15. 15. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krucger S, Young S, Shusterman N, for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-2816.
16. 16. Pfeffer MA, Stevenson LW. β-adrenergic blockers and survival in heart failure. N Engl J Med 1996;334:1396-1397.
17. 17. Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Kaplinsky E, Graff E, Kishon Y, Caspi A, Weisbort J, Mandelzweig L, Abinader E, Aharon L, Braun S, David D, Flich M, Friedman Y, Kristal N, Leil N, Markiewicz W, Marmor A, Palant A, Felled B, Rabinowitz B, Reisin L, Roguin N, Rosenfeld T, Schlesinger Z, Sclarovsky S, Sher L, Tzivoni D, Zahavi I, Zion M, for the BIP Study group. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention trial). Am J Cardiol 1993:909-915.
18. 18. Criteria Committee, New York Heart Association, Inc. Diseases of the Heart and Blood Vessels. Nomenclature and Criteria for Diagnosis. 6th ed. Boston: Little, Brown, 1964:114.
19. 19. SAS Institute Inc. SAS/STAT software: changes and enhancements through release 6.11. Cary, NC: SAS Institute Inc., 1996.
20. 20. Kennedy HL, Brooks MM, Baker MM, Bergstrandt R, Huther ML, Beanlands DS, Bigger JT, Goldstein S, for the CAST Investigators. Beta-blocker therapy in the cardiac arrhythmia suppression trial. Am J Cardiol 1994;74:674-680.
21. 21. Krum H, Sackner-Bernstein J, Goldsmith LR, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz M, Levin HR, Neuberg GW, Delong G, Packer M. Double-blind, placebo controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92: 1499-1506.
22. 22. Woodley SL, Gilbert EM, Anderson JL, O'Connell JL, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund D, Menlore R, Bristow MR. β-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-2441.
23. 23. Vantrimpont P, Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex B, Arnold MO, Moye L, Pfeffer M, for the SAVE Investigators. Additive beneficial effects of beta-blockers to angiotensin converting enzyme inhibitors in the survival and ventricular enlargement (SAVE) study. J Am Coll Cardiol 1997;29:229-236.
24. 24. Eichorn EJ, Bedotto JB, Malloy CR, Hatfield BA, Deitchman D, Brown M, Willard JE, Grayburn PA. Effect of β-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvement in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 1990;82:473-483.
25. 25. Pilatti CF, Bosso FJ, Maron MB. Factors involved in left ventricular dysfunction after massive sympathetic activation. Am J Physiol 1992; 63:784-791.
26. 26. Bristow MR, Anderson FL, Port D, Skert L, Hershberger RE, Larrabee P, O'Connell JE, Renlund DG, Volkman K, Murray J, Feldman AM. Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:1024-1039.
27. 27. Pratt C, Lichstein E. Ventricular antiarrythmic effects of of beta adrenergic blocking drugs: a review of mechanism and clinical studies. J Clin Pharmacol 1982;335-347.
28. 28. Ryden L, Ariniego R, Arnman K, Herlitz J, Hjalmarson A, Holmberg S, Reyes C, Smedgard P, Svedberg K, Vedin A, Waagstein P, Waldenstrom A, Wilhelmsson C, Wedel H, Yamamoto M. A double-blind trial of metoprolol in acute myocardial infarction: effects on ventricular tachyarrhythmias. N Engl J Med 1983;308:614-620.
29. 29. Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in postinfarction patients. Eur Heart J 1988;9:8-16.
30. 30. Herlitz J, Hjalmarson A, Holmberg S, Swedberg K, Vedin A, Waagstein F, Waldenstrom A, Waedel H, Wilhelmsen E, Wilhelmsson C. Development of congestive heart failure after treatment with metoprolol in acute myocardial infarction. Br Heart J 1984;51:539-544.